P. Kerbrat

发表

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.

J. Bonneterre, A. Monnier, I. van Praagh, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer.

A. Ravaud, J. Wanders, N. Pavlidis, 2003, European journal of cancer.

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge

P. Kerbrat, B. Laguerre, H. Mesbah, 2010, Cancer Chemotherapy and Pharmacology.

Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial

M. Namer, J. Bonneterre, A. Monnier, 2007, British Journal of Cancer.

Taxanes in adjuvant breast cancer setting: which standard in Europe?

M. Campone, P. Fumoleau, P. Kerbrat, 2005, Critical reviews in oncology/hematology.

Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.

T. Delozier, J. Petit, B. Weber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)

M. Héry, T. Delozier, M. Namer, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Patients' regrets after participating in a randomized controlled trials depended on their involvement in the decision making.

P. Viens, J. Mancini, C. Tarpin, 2012, Journal of clinical epidemiology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

T. Delozier, J. Bonneterre, B. Asselain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.

M. Namer, J. Bonneterre, A. Monnier, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.

A. Monnier, C. Tarpin, F. Dalenc, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized double-blind study evaluating anandron® associated with orchiectomy in stage D prostate cancer

M. Namer, J. Droz, P. Kerbrat, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Adjuvant ovarian suppression in premenopausal breast cancer.

A. Giobbie-Hurder, E. Winer, R. Gelber, 2015, The New England journal of medicine.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

F. Bertucci, J. Lemonnier, J. Bonneterre, 2016, The Lancet. Oncology.

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.

C. Haie-meder, F. Bertucci, B. Weber, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case‐control study with radiotherapy alone

C. Haie-meder, P. Morice, P. Kerbrat, 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Participants’ uptake of clinical trial results: a randomised experiment

P. Viens, J. Mancini, C. Tarpin, 2010, British Journal of Cancer.

Night work and breast cancer: A population‐based case–control study in France (the CECILE study)

P. Guénel, T. Truong, F. Menegaux, 2013, International journal of cancer.

Decision-making and breast cancer clinical trials: how experience challenges attitudes.

A. Monnier, J. Mancini, C. Tarpin, 2007, Contemporary clinical trials.

Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1996, European journal of cancer.

Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases

M. Namer, C. Jacquillat, D. Khayat, 1990, Cancer.

Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer

J. Bonneterre, M. Campone, S. Urien, 2003, Cancer Chemotherapy and Pharmacology.

Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases.

C. Borel, M. Provencio, J. Bogart, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.

T. Delozier, M. Namer, A. Monnier, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)

M. Mathieu, J. Lemonnier, V. Bécette, 2016, Cancer.

Current status of Taxotere® (docetaxel) as a new treatment in breast cancer

M. Glabbeke, P. Fumoleau, V. Diéras, 2004, Breast Cancer Research and Treatment.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

F. Bertucci, F. André, J. Lemonnier, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast

Julian Peto, Matthias W. Beckmann, Peter A. Fasching, 2014, PLoS genetics.

High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).

F. Mayer, F. Joly, J. Macé-Lesec’h, 2000, Gynecologic oncology.

French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies.

E. Lespessailles, J. Bonneterre, K. Briot, 2019, Joint, bone, spine : revue du rhumatisme.

Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases.

C. Haie-meder, S. Culine, P. Morice, 2011, European journal of cancer.

Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.

M. Nooij, I. Vergote, D. Wagener, 2001, European Journal of Gynaecological Oncology.

Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.

F. André, J. Lemonnier, J. Bonneterre, 2015 .

Breast cancer risk , night work and circadian clock gene polymorphisms 1 2

P. Guénel, T. Truong, F. Menegaux, 2014 .

A phase II study of M-azido-pyrimethamine ethane sulphonate (MZPES) in advanced, recurrent soft tissue sarcoma. An EORTC Soft Tissue and Bone Sarcoma Group Study.

H. Keizer, J. Verweij, R. Sylvester, 1989, European journal of cancer & clinical oncology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type.

F. Mayer, P. Morice, P. Kerbrat, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience.

J. Droz, M. Spielmann, P. Fargeot, 1991, European journal of cancer.

A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13.

S. Culine, C. Logothetis, G. Gravis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial.

P. Biron, J. Droz, P. Fargeot, 1993, European urology.

Acute ischemia of the lower limb during chemotherapy for testicular cancer: A report of two cases

P. Kerbrat, J. Raoul, E. Vauléon, 2009, Acta oncologica.

[On the subject of the recommendations for clinical practice: 2003 Standards, Options and Recommendations for the medical frontline treatment of patients with malignant epithelial ovarian tumors. Update (summary version)].

P. Kerbrat, 2004, Gynecologie, obstetrique & fertilite.

Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases.

S. Culine, C. Logothetis, G. Le Teuff, 2017, European journal of cancer.

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

N. Girard, J. Blay, F. Collin, 2014, European journal of cancer.

A randomised trial of maintenance therapy for non metastatic inflammatory breast cancer (IBC)

T. Delozier, P. Kerbrat, C. Noguès, 1993 .

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.

M. van Glabbeke, J. Verweij, A. V. van Oosterom, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III Trial of Early Intensified Chemotherapy (HDCT) with Autologous Bone Marrow Transplantation (ABMT) in First Line Treatment of Poor Risk Non-Seminomatous Germ Cell Tumours (NSGCT): Long Term Results of a Randomised Trial

P. Biron, J. Droz, P. Fargeot, 1994 .

Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature.

C. Haie-meder, S. Delaloge, P. Kerbrat, 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.

M. Namer, J. Bonneterre, M. Campone, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.

J. Bergh, M. Piccart, R. Coombes, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

S. Schraub, M. Namer, J. Bonneterre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors of contralateral breast cancer (CBC) in 3,653 early breast cancer (EBC) patients (pts): 9-year follow-up results of French Adjuvant Study Group (FASG) trials.

M. Namer, J. Bonneterre, A. Monnier, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Leukemia and pre-leukemic conditions occurring after treatment of breast cancer].

J. Julien, P. Kerbrat, H. Lauche, 2000, Presse medicale.

Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy

P. Fumoleau, P. Fargeot, P. Kerbrat, 2006, Cancer.

The antiemetic efficacy and safety of granisetron compared with metoclopramide plus dexamethasone in patients receiving fractionated chemotherapy over 5 days

V. Diehl, D. Dearnaley, H. Keizer, 1993, Journal of Cancer Research and Clinical Oncology.

Breast cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: analysis of 214 cases.

L. Livi, M. Provencio, P. Kerbrat, 2012, Critical reviews in oncology/hematology.

10-year follow-up update of French adjuvant study group 05 trial: FEC 100 regimen remains superior to FEC 50 in adjuvant chemotherapy of poor prognosis, node-positive, early breast cancer patients

M. Namer, J. Bonneterre, P. Fumoleau, 2003 .

Short term vs lifelong adjuvant tamoxifen in early breast cancer (EBC): A randomized trial (TAM-01)

T. Delozier, J. Petit, B. Weber, 1997 .

Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.

M. Namer, P. Kerbrat, R. Bugat, 1989, Seminars in oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

P. Biron, J. Droz, P. Fargeot, 1994 .

[Nonsurgical treatment of hepatocellular carcinoma].

P. Kerbrat, J. Raoul, E. Boucher, 1999, Bulletin du cancer.

Prognostic significance of an early decline in serum alpha-fetoprotein during chemotherapy for ovarian yolk sac tumors.

C. Haie-meder, C. Genestie, S. Culine, 2016, Gynecologic oncology.

Preliminary results of a phase II study to evaluate gefitinib (ZD1839) combined with paclitaxel (P) and carboplatin (C) as second-line therapy in patients (pts) with ovarian carcinoma (OC)

T. Petit, F. Ringeisen, P. Fumoleau, 2004 .

Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

J. Bonneterre, M. Campone, S. Urien, 2004, Cancer Chemotherapy and Pharmacology.

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.

S. Salas, A. Italiano, J. Thariat, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma

C. Jacquillat, D. Khayat, P. Fumoleau, 2004, Cancer Chemotherapy and Pharmacology.

Hereditary epidermolytic palmoplantar keratoderma associated with breast and ovarian cancer in a large kindred

M. Espié, P. Kerbrat, C. Blanchet‐Bardon, 1987, The British journal of dermatology.

Determinants of serum concentrations of 1,1-dichloro-2,2-bis(p-chlorophenyl)ethylene and polychlorinated biphenyls among French women in the CECILE study.

P. Guénel, T. Truong, C. Guihenneuc‐Jouyaux, 2011, Environmental research.

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

J. Blay, B. Bui, C. Fournier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three cases of sarcoma occurring after radiation therapy of breast cancers.

P. Kerbrat, B. Meunier, J. Levêque, 1994, European journal of obstetrics, gynecology, and reproductive biology.

Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial

J. Blay, C. Fournier, I. Ray-Coquard, 2007 .

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

C. Balleyguier, A. Leary, J. Droz, 2014, European journal of cancer.

Level of plasma fibronectin in patients with breast cancer.

P. Kerbrat, B. Legras, C. Clerc, 1988, Clinica chimica acta; international journal of clinical chemistry.

Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma

M. Namer, P. Fumoleau, P. Kerbrat, 1990, Cancer Chemotherapy and Pharmacology.

Phase II clinical evaluation of doxifluridine.

S. Schraub, J. Armand, P. Fumoleau, 1986, Cancer treatment reports.

Genome-wide association studies identify four ER negative–specific breast cancer risk loci

Patrick Neven, Michael Jones, Wei Lu, 2013, Nature Genetics.

Genetic heterogeneity of early-onset familial breast cancer

S. Mazoyer, S. Narod, H. Sobol, 1992, Human Genetics.

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

J. Blay, B. Bui, A. Le Cesne, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Women with Isolated Adenocarcinoma in the Axillary Lymph Node of an Unknown Primary Site

P. Kerbrat, A. Lortholary, J. Ramée, 2006 .

Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

Jane E. Carpenter, Kyriaki Michailidou, France Labrèche, 2014, Human molecular genetics.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer risk, nightwork, and circadian clock gene polymorphisms.

P. Guénel, T. Truong, P. Laurent-Puig, 2014, Endocrine-related cancer.

Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors

P. Morice, P. Kerbrat, P. Duvillard, 2007, International Journal of Gynecologic Cancer.

Improved survival using specialized multidisciplinary board in sarcoma patients.

J. Blay, F. Bertucci, S. Bonvalot, 2017 .

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

T. Petit, F. Ringeisen, P. Fumoleau, 2010, Gynecologic oncology.

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

P. Fumoleau, P. Fargeot, P. Kerbrat, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Peritoneal pseudomyxoma and mucinous ovarian cystadenocarcinoma. Apropos of 3 cases].

P. Kerbrat, D. Guérin, J. Cardin, 1983, Annales de chirurgie.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

Phase II trial of methylene dimethane sulphonate (MDMS) in advanced soft tissue sarcomas of the adult. A study of the EORTC Soft Tissue and Bone Sarcoma Group.

J. Verweij, R. Sylvester, H. Mouridsen, 1989, European journal of cancer & clinical oncology.

Unusual cause of recurrent pneumothorax: excavated metastasis of osteosarcoma.

P. Kerbrat, H. Léna, P. Delaval, 2001, The Annals of thoracic surgery.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

J. Baselga, K. Krejcy, M. Namer, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

M. Buyse, M. Namer, F. Penault-Llorca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

M. van Glabbeke, M. Glabbeke, P. Fumoleau, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.

T. Petit, V. Diéras, P. Kerbrat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved survival using specialized multidisciplinary board in sarcoma patients

F. Bertucci, S. Bonvalot, A. Cesne, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1994 .

Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).

J. Lemonnier, B. Asselain, M. Campone, 2017, European journal of cancer.

Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer.

M. Namer, P. Kerbrat, C. Lhommé, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.

J. Bonneterre, A. Monnier, P. Fumoleau, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

A. Ravaud, P. Hérait, A. Zannetti, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

J. Sparano, L. Mauriac, D. Lebwohl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial

F. Penault-Llorca, J. Lemonnier, J. Canon, 2013, Breast Cancer Research and Treatment.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.

J. Blay, F. Bertucci, A. Cesne, 2016 .

The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment

J. Blay, F. Bertucci, A. Cesne, 2016 .

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years

J. Blay, F. Bertucci, O. Mir, 2019, International journal of cancer.

[Breast carcinoma metastasis into a renal cell carcinoma].

N. Rioux-Leclercq, P. Kerbrat, D. Chiforeanu, 2011, Annales de pathologie.

Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1.

T. Delozier, F. André, J. Bonneterre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

S. Culine, P. Biron, C. Théodore, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial.

S. Culine, P. Biron, C. Théodore, 2007, European urology.

[Axillary lymph node microcalcifications disclosing breast cancer].

P. Kerbrat, P. Bourguet, P. Fleury, 1997, Journal de radiologie.

Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents

A. Schally, P. Kerbrat, J. Misset, 1986, The Prostate.

An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma

A. Schally, P. Kerbrat, J. Misset, 1984, Medical oncology and tumor pharmacotherapy.

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

D. Lacombe, C. Punt, X. Paoletti, 2003, Investigational New Drugs.

Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.

J. Bonneterre, P. Fargeot, P. Kerbrat, 1991, European journal of cancer.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

M. Espié, D. Khayat, G. Romieu, 2013, The Lancet. Oncology.

Phase II study of cystemustine in metastatic colorectal carcinoma. A trial of the EORTC Clinical Screening Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1993, European journal of cancer.

[Excision of an intracardiac metastasis under chemotherapy].

P. Kerbrat, D. Gédouin, C. Toussaint, 1990, Journal de Chirurgie.

Weight and weight changes throughout life and postmenopausal breast cancer risk: a case-control study in France

P. Guénel, T. Truong, P. Arveux, 2016, BMC Cancer.

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

S. Schraub, M. Namer, A. Monnier, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node‐positive, early‐stage, invasive breast carcinoma undergoing breast‐conserving surgery

A. Courdi, A. Monnier, D. Berton‐Rigaud, 2005, Cancer.

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.

P. Fumoleau, V. Diéras, P. Kerbrat, 1996, British Journal of Cancer.

UFT/leucovorin plus vinorelbine combination for advanced breast cancer.

J. Bonneterre, P. Fumoleau, P. Fargeot, 2000, Oncology.

UFT plus oral calcium folinate/vinorelbine for advanced breast cancer.

P. Fumoleau, P. Kerbrat, B. Laguerre, 1999, Oncology.

UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer.

H. Wildiers, J. Lemonnier, M. Lacroix-Triki, 2018, European journal of cancer.

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

A. Vincent-Salomon, T. Delozier, M. Namer, 2010, The oncologist.

Recurring atypical ("pseudosarcomatous") cutaneous fibrous histiocytoma.

J. Coindre, P. Kerbrat, H. Adamski, 1998, European journal of dermatology : EJD.

Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor.

C. Haie-meder, S. Culine, P. Morice, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer risk by occupation and industry: analysis of the CECILE study, a population-based case-control study in France.

O. Gaye, P. Guénel, T. Truong, 2011, American journal of industrial medicine.

[Standards, options and recommendations for the management and initial care of patients with malignant epithelial ovarian tumors (abridged version)].

B. Fervers, T. Bachelot, P. Kerbrat, 2001, Gynécologie Obstétrique & Fertilité.

Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

Ludovic Ferrer, Pierre Kerbrat, Caroline Rousseau, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC).

J. Armand, P. Fumoleau, P. Kerbrat, 1993, European journal of cancer.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation

S. Culine, P. Biron, J. Droz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France

P. Guénel, T. Truong, P. Arveux, 2013, PloS one.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

S. Culine, C. Logothetis, G. Gravis, 2014, The Lancet. Oncology.

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, 2019, Journal of adolescent and young adult oncology.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Thomas Bachelot, Thierry Petit, Pierre Kerbrat, 2014, The Lancet. Oncology.

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research.

Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone

C. Haie-meder, P. Morice, P. Kerbrat, 2004, International Journal of Gynecologic Cancer.

Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up.

P. Fumoleau, Anne-Laure Martin, F. Dalenc, 2012, Bulletin du cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

T. Delozier, M. Namer, J. Bonneterre, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pirarubicin in advanced breast cancer: a French cooperative phase II study.

T. Delozier, M. Namer, A. Monnier, 1990, European journal of cancer.

Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards.

J. Blay, F. Bertucci, A. Cesne, 2012 .

Primary osteosarcomas of the mandible: Joint study of the Groupe Sarcome Francais (GSF), Rare Cancer Network, and Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC).

S. Salas, J. Thariat, H. Reychler, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of elliptinium in advanced renal cell carcinoma.

C. Théodore, J. Droz, P. Kerbrat, 1985, Cancer treatment reports.

Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group.

M. Namer, J. Bonneterre, M. Campone, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

D. Cox, H. Bonnefoi, G. Romieu, 2017, European journal of cancer.

Premenopausal Patients with Node-Positive Resectable Breast Cancer

S. Schraub, M. Namer, P. Fumoleau, 2012, Drugs.

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

B. Asselain, M. Campone, T. Petit, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Weight and weight changes throughout life and postmenopausal breast cancer risk: a case-control study in France

P. Guénel, T. Truong, P. Arveux, 2016, BMC Cancer.

Phase II study of 1,2,4-triglycidyl urasol (TGU) in advanced soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Cooperative Group.

A. V. van Oosterom, P. Kerbrat, J. Rouëssé, 1987, European journal of cancer & clinical oncology.

A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.

C. Théodore, P. Kerbrat, K. Fizazi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

M. Espié, M. Dowsett, R. Gelber, 2012 .

[Extraosseous Ewing's sarcoma of the spinal epidural space].

X. Morandi, L. Riffaud, C. Haegelen, 2001, Neuro-Chirurgie.

Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.

P. Fumoleau, P. Kerbrat, P. Chollet, 1998, European journal of cancer.

Does time interval between surgery and adjuvant chemotherapy initiation modify treatment efficacy in operable, breast cancer patients? French Adjuvant Study Group (FASG) results

M. Namer, J. Bonneterre, A. Monnier, 2005 .

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

M. Espié, D. Khayat, G. Romieu, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[Massive hepatic necrosis secondary to treatment of hepatocellular carcinoma by percutaneous alcoholization].

P. Kerbrat, J. Raoul, E. Boucher, 1998, Gastroenterologie clinique et biologique.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

Night work and breast cancer risk defined by human epidermal growth factor receptor-2 (HER2) and hormone receptor status: A population-based case–control study in France

P. Guénel, T. Truong, F. Menegaux, 2016, Chronobiology international.

Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.

P. Fumoleau, P. Kerbrat, C. Lhommé, 1996, Seminars in oncology.

[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)].

C. Tournigand, B. Fervers, A. Bataillard, 2004, Bulletin du cancer.

The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.

D. Crowther, J. Verweij, T. Tursz, 1993, Cancer chemotherapy and pharmacology.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.

K. Bensalah, N. Rioux-Leclercq, A. Ravaud, 2015 .

5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study.

R. Rouzier, B. Pistilli, L. Vanlemmens, 2018, European journal of cancer.

Phase II Trials of Tetrahydropyranyl‐Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma

P. Hérait, J. Armand, P. Fumoleau, 1993, American journal of clinical oncology.

Epirubicin‐Docetaxel Combination in First‐Line Chemotherapy for Patients With Metastatic Breast Cancer: Final Results of a Dose‐Finding and Efficacy Study

T. Delozier, P. Viens, P. Fumoleau, 2001, American journal of clinical oncology.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of cystemustine in advanced eenal cancer

J. Madelmont, V. Diéras, P. Fargeot, 1995 .

Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory.

F. Denis, P. Kerbrat, J. Metges, 2009 .

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

F. Bertucci, D. Birnbaum, P. Finetti, 2011, Breast Cancer Research.

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.

A. Italiano, J. Thariat, P. Maingon, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Syndrome de Stewart-Treves sur lymphœdème chronique post-traumatique

M. Hassel, P. Kerbrat, C. Lefeuvre, 1999 .

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

S. Culine, A. Laplanche, P. Kerbrat, 2014, European urology.

Acute leukemia following testicular carcinoma.

P. Kerbrat, P. Le Prise, 1985, Journal of Clinical Oncology.

[Physical activity and cancer survival].

B. Fervers, I. Romieu, G. Romieu, 2012, Bulletin du Cancer.

C. Haie-meder, F. Bertucci, I. Ray-Coquard, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

P. Neven, R. Gelber, A. Goldhirsch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Post-treatment follow-up of breast cancer patients: comments on the guidelines of the American Society of Clinical Oncology (ASCO)].

P. Kerbrat, B. Laguerre, C. Lefeuvre, 1997, Bulletin du cancer.

Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer

M. Espié, H. Bonnefoi, D. Khayat, 2012 .

Phase II study with taxotere(RP56976) in advanced soft tissue sarcomas of the adult

J. Verweij, M. Glabbeke, H. Mouridsen, 1993 .

Phase II study of epirubicin in advanced soft tissue sarcoma.

P. Kerbrat, P. Montcuquet, P. Bastit, 1990, Bulletin du cancer.

P4-20-01: Multicentric Phase II PACS 09/Beverly1 Trial: First Efficacy and Safety Results of Neoadjuvant Chemotherapy Combined with Bevacizumab in HER2−Negative Patients with Non-Metastatic Inflammatory Breast Cancer.

T. Delozier, F. André, J. Lemonnier, 2011 .

[Breast carcinoma metastasis into a renal cell carcinoma].

N. Rioux-Leclercq, P. Kerbrat, D. Chiforeanu, 2011, Annales de pathologie.